Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.14 USD

806.14
3,911,551

-12.79 (-1.56%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $801.00 -5.14 (-0.64%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids

by Zacks Equity Research

Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.

Lilly Gets CHMP Nod to Add Heart Indication to Trulicity Label

by Zacks Equity Research

CHMP gives positive opinion to add cardiovascular risk reduction data from the REWIND outcomes study on the label of Lilly's (LLY) diabetes medicine, Trulicity.

Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck

by Zacks Equity Research

Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.

AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure

by Zacks Equity Research

The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.

Kinjel Shah headshot

Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert

by Kinjel Shah

The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.

Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

by Zacks Equity Research

Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival

Kinjel Shah headshot

Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others

by Kinjel Shah

Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.

Sanghamitra Saha headshot

Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Pfizer's Pneumococcal Vaccine Shows Potential in Infants

by Zacks Equity Research

Pfizer (PFE) announces positive preliminary data from mid-stage study evaluating its 20-valent pneumococcal conjugate vaccine in infants. Completes enrollment in late-stage studies on the vaccine in adults.

Are You Looking for a High-Growth Dividend Stock? Eli Lilly (LLY) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Mark Vickery headshot

Top Analyst Reports for Caterpillar, General Motors & Citigroup

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Caterpillar (CAT), General Motors (GM) and Citigroup (C).

Lilly's RET Inhibitor Shrinks Tumors in Lung Cancer Study

by Zacks Equity Research

Lilly (LLY) presents data from the LIBRETTO-001 study on selpercatinib for the treatment of RET fusion-positive non-small cell lung cancer. The candidate as a monotherapy attains 68% ORR.

Novartis Announces Positive Long-Term Data on Migraine Drug

by Zacks Equity Research

Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.

AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC

by Zacks Equity Research

AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.

J&J's Stelara Gets Approval in EU for Ulcerative Colitis

by Zacks Equity Research

Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).

Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M

by Zacks Equity Research

Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.

The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie

by Zacks Equity Research

The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie

5 Cancer-Fighting Stocks to Add to Your Portfolio

by Zacks Equity Research

Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs

by Kinjel Shah

Oklahoma imposes fine of $572 million on J&J (JNJ). FDA gives nod to Lilly's (LLY) Taltz while EU approves Bristol-Myers' (BMY) Empliciti and Roche's (RHHBY) Tecentriq for expanded patient population.

Lilly (LLY) Up 1.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Christopher Vargas headshot

J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?

by Christopher Vargas

An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.

Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis

by Zacks Equity Research

The FDA approves Eli Lilly's (LLY) Taltz injection for the treatment of adult patients with active ankylosing spondylitis. Shares rise.

AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome

by Zacks Equity Research

The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to delay progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.

Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study

by Zacks Equity Research

Lilly (LLY) is conducting five studies on Olumiant (baricitinib) under the atopic dermatitis (AD) program and BREEZE-AD7 is the third study to be completed this year.

AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China

by Zacks Equity Research

AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.